Business

Novartis Seeks U.S. Approval for Two Smoker’s Cough Drugs

  (Bloomberg) – Novartis AG applied for U.S. regulatory approval for two drugs to treat smoker’s cough that analysts estimate could generate an additional $1.4 billion in annual sales for the Swiss drugmaker. Third-phase clinical tests for QVA149 and NVA237 showed “positive” results for the treatment of Read More

Advertisements